Analysis of 15 STEMI patients revealed that creatine kinase-MB (CK-MB) and total creatine phosphokinase (CPK) were elevated in 80% of cases, with 73% showing concordant elevation indicating extensive heart muscle death. These enzymes demonstrated significant correlation (r = 0.615), while troponin-I showed the highest sensitivity at 87% elevation. The findings suggest these traditional cardiac markers maintain clinical utility in resource-constrained healthcare settings where newer troponin tests may be unavailable. This represents a practical consideration for global cardiac care, as CK-MB and CPK remain more accessible and cost-effective than high-sensitivity troponins in many regions. However, several limitations warrant caution: the extremely small sample size of just 15 patients severely limits statistical power and generalizability. The single-center, cross-sectional design cannot establish prognostic outcomes over time, despite the title's promise of predicting adverse events. Additionally, this preprint has not undergone peer review, so these preliminary results require validation in larger cohorts before clinical application. While the study confirms known biochemical relationships, it provides incremental rather than transformative insights into STEMI biomarker utility.